Advertisement
Research Article

Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009)

  • Urvi M. Parikh mail,

    ump3@pitt.edu

    Affiliation: Department of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America

    X
  • Photini Kiepiela,

    Affiliation: HIV Prevention Research Unit, Medical Research Council, Durban, South Africa

    X
  • Shayhana Ganesh,

    Affiliation: HIV Prevention Research Unit, Medical Research Council, Durban, South Africa

    X
  • Kailazarid Gomez,

    Affiliation: FHI 360, Research Triangle Park, North Carolina, United States of America

    X
  • Stephanie Horn,

    Affiliation: FHI 360, Research Triangle Park, North Carolina, United States of America

    X
  • Krista Eskay,

    Affiliation: Department of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America

    X
  • Cliff Kelly,

    Affiliation: Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

    X
  • Barbara Mensch,

    Affiliation: Population Council, New York, New York, United States of America

    X
  • Pamina Gorbach,

    Affiliation: Department of Epidemiology, University of California Los Angeles, Los Angeles, California, United States of America

    X
  • Lydia Soto-Torres,

    Affiliation: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Gita Ramjee,

    Affiliation: HIV Prevention Research Unit, Medical Research Council, Durban, South Africa

    X
  • John W. Mellors,

    Affiliation: Department of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America

    X
  • on behalf of the IPTc Taskforce

    Membership of the MTN-009 Protocol Team is provided in the Acknowledgments

    X
  • Published: April 09, 2013
  • DOI: 10.1371/journal.pone.0059787

About the Authors

Urvi M. Parikh, Krista Eskay, John W. Mellors
Department of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
Photini Kiepiela, Shayhana Ganesh, Gita Ramjee
HIV Prevention Research Unit, Medical Research Council, Durban, South Africa
Kailazarid Gomez, Stephanie Horn
FHI 360, Research Triangle Park, North Carolina, United States of America
Cliff Kelly
Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
Barbara Mensch
Population Council, New York, New York, United States of America
Pamina Gorbach
Department of Epidemiology, University of California Los Angeles, Los Angeles, California, United States of America
Lydia Soto-Torres
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

Corresponding Author

Email: ump3@pitt.edu

Competing Interests

The co-authors UMP, PK, SG, KG, SH, KE, CK, BM, PG, LS-T, and GR have declared that no competing interests exist. JM has read the journal’s policy and has the following conflicts: University of Pittsburgh–Employee; RFS Pharmaceuticals–Consultant, owns shares in shre options; Gilead Sciences–Consultant; and, Janssen Pharmaceuticals–Honorarium. JM’s conflicts do not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: UMP PK SG KG SH BM PG LST. Performed the experiments: PK SG KE. Analyzed the data: UMP KE CK BM PG. Wrote the paper: UMP BM PG GR JWM.